We conducted a meta-analysis of 13 randomized trials comparing the efficacy of rosuvastatin versus atorvastatin in reducing concentrations of C-reactive protein (CRP). We searched PubMed, Ovid, and Elsevier databases until June 2014. Search terms included C-reactive protein or CRP, rosuvastatin, atorvastatin, randomized, randomly, and randomization; 13 trials (3798 patients) were included. Funnel plots for CRP were inspected to assess publication bias. The pooled analysis demonstrated the benefit of rosuvastatin over atorvastatin therapy for all 13 trials (mean difference [MD] = −0.11, which is standardized mean with no unit although the raw data before pooling is mg/L, 95% confidence interval −0.15 to −0.07, P < .0001) with no evidence of significant publication bias (I2 = 6.9%, P = .377). Subgroup analysis indicated a significant benefit of rosuvastatin over atorvastatin regarding the 1/1 dose ratio (MD = −0.14, 95% CI −0.21 to −0.06) and 1/2 dose ratio (MD= −0.11, 95% CI −0.16 to −0.05). Cumulative and influence analyses showed accuracy and stability for the estimation mentioned earlier. Our meta-analysis shows that rosuvastatin produces better reduction in CRP concentrations than atorvastatin at a dose ratio of 1/1 and 1/2 (rosuvastatin/atorvastatin), respectively.
AfilaloJMajdanAAEisenbergMJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart. 2007;93(8):914–921.
2.
PattiGCannonCPMurphySA. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation. 2011;123(15):1622–1632.
3.
NavareseEPKowalewskiMAndreottiF. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol. 2014;113(10):1753–1764.
4.
NichollsSJBrandrup-WognsenGPalmerMBarterPJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69–76.
5.
RabarSHarkerMO’FlynnNWierzbickiAS, Guideline Development Group. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. BMJ. 2014;349:g4356.
6.
TakagiHUmemotoT, ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles. Am J Cardiol. 2014;113(2):292–301.
7.
NozueTFukuiKYamamotoS. C-reactive protein and future cardiovascular events in statin-treated patients with angina pectoris: the extended TRUTH study. J Atheroscler Thromb. 2013;20(9):717–725.
8.
PuriRNissenSELibbyP. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013;128(22):2395–2403.
9.
TakagiHUmemotoT. A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein. Int J Cardiol. 2012;154(1):78–81.
10.
NichollsSJBallantyneCMBarterPJ. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–2087.
11.
VolminkJSiegfriedNRobertsonKGülmezogluAM. Research synthesis and dissemination as a bridge to knowledge management: the Cochrane Collaboration. Bull World Health Organ. 2004;82(10):778–783.
12.
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
13.
HigginsJPThompsonSGSpiegelhalterDJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc. 2009;172(1):137–159.
14.
RileyRDHigginsJPDeeksJJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.
15.
SteinEAStruttKSouthworthHDigglePJMillerE, HeFH Study Group. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003;92(11):1287–1293.
16.
FerdinandKCClarkLTWatsonKE. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006;97(2):229–235.
17.
MilionisHJRizosEKostapanosM. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. 2006;22(6):1123–1131.
18.
BetteridgeDJGibsonJMSagerPT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol. 2007;100(8):1245–1248.
19.
BrunettiNDMaulucciGCasavecchiaGP. Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg. J Interv Cardiol. 2007;20(6):481–487.
20.
KaralisIKBergheanuSCWolterbeekR. Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Curr Med Res Opin. 2010;26(10):2301–2313.
21.
HongYJJeongMHHachinoheD. Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circ J. 2011;75(2):398–406.
22.
ThongtangNAiMOtokozawaS. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol. 2011;107(3):387–292.
23.
SakuKZhangBNodaK, PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ J. 2011;75(6):1493–505.
24.
AnagnostisPSelalmatzidouDPolyzosSA. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. Int J Clin Pract. 2011;65(6):679–683.
25.
TsutamotoTSakaiHIbeK. Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy. Circ J. 2011;75(9):2160–2166.
26.
NichollsSJBallantyneCMBarterPJ. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–2087.
27.
LiuBCaoHMLiGY. Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis. J Int Med Res. 2011;39(6):2314–2322.
28.
LabosCWangRHPiloteL. Traditional risk factors and a Genetic Risk Score are associated with age of first acute coronary syndrome. Heart. 2014;100(20):1620–1624.
29.
BlumA. HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis. Biofactors. 2014;40(3):295–302.
30.
WangXHLiuSQWangYLJinY. Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome. Genet Mol Res. 2014;13(2):4260–4266.
31.
CozleaDLFarcasDMNagyA. The impact of C reactive protein on global cardiovascular risk on patients with coronary artery disease. Curr Health Sci J. 2013;39(4):225–231.
32.
ThieleJRHabersbergerJBraigD. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation. 2014;130(1):35–50.
33.
Emerging Risk Factors Collaboration, KaptogeSDi AngelantonioE. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–1320.
34.
EapenDJManochaPPatelRS. Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J Am Coll Cardiol. 2013;62(4):329–337.
35.
NeadKTZhouMJCaceresRD. Usefulness of the addition of beta-2-microglobulin, cystatin C and C-reactive protein to an established risk factors model to improve mortality risk prediction in patients undergoing coronary angiography. Am J Cardiol. 2013;111(6):851–856.
36.
EverettBMGlynnRJMacFadyenJG. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121(1):143–150.
37.
KonesR. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther. 2010;4:383–413.
38.
KheraAVEverettBMCaulfieldMP. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation. 2014;129(6):635–642.
39.
DehghanADupuisJBarbalicM. Meta-analysis of genomewide association studies in >80,000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011;123(7):731–738.
40.
KoenigW. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013;168(6):5126–5134.
41.
Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011;377(9764):469–476.
42.
RidkerPMMacFadyenJLibbyPGlynnRJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 2010;106(2):204–209.
43.
YousufOMohantyBDMartinSS. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?J Am Coll Cardiol. 2013;62(5):397–408.
44.
BaigentCBlackwellLEmbersonJ. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
45.
YogoMSasakiMAyaoriM. Intensive lipid lowering therapy with titrated rosuvastatin yields greater atherosclerotic aortic plaque regression: Serial magnetic resonance imaging observations from RAPID study. Atherosclerosis. 2014;232(1):31–39.
46.
RidkerPMRifaiNPfefferMA. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98(9):839–844.
47.
RidkerPMCannonCPMorrowD. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–28.
48.
NissenSETuzcuEMSchoenhagenP. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29–38.
49.
MorrowDAde LemosJASabatineMS. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation. 2006;114(4):281–288.
50.
SardellaGLucisanoLManconeM. Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial. Int J Cardiol. 2013;168(4):3715–3720.
